News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

Biosyntrx Corporation Macula Complete(TM) Formula Cited "Best In Class" And "Most Economical And Complete" By Leading Macular Degeneration Website

10/19/2005 5:11:48 PM

LEXINGTON, S.C., Oct. 19 /PRNewswire/ -- Biosyntrx, a research-based ophthalmic company providing nutraceutical products that support optimal eye and body health, today announced that its Macular Complete product has received the endorsement of Macular Degeneration Support, the award-winning, worldwide Internet-based information and support community for people affected by macular degeneration and similar retinal diseases.

Macula Complete(TM) is a full-spectrum multiple designed for the age-related macular degeneration (AMD) patient who requires maximum support for the macula and potent nutritional support for the entire body.

Founded in 1995, MD Support is an independent, non-profit organization which as a practice eschews product recommendations. Nevertheless, Dan Roberts, founder and director of MD Support, lauded Macular Complete in an e-mail to the organization's members earlier this month:

"Having recently overviewed all of the supplements designed for MD patients, one stands out as probably the most effective and economical. The product is Macula Complete, distributed by Biosyntrx, Inc. It includes the ingredients recommended by recent research, including the AREDS formula, the Phototrop formula, and the Lutein Antioxidant Supplement Trial (LAST) study. Macula Complete includes Vitamin A, as retinyl palmitate, and less than 1.5 mg of beta-carotene. This is for smokers who are concerned about the studies showing beta-carotene as a potential risk factor for developing lung cancer. "This appears to be the most all-inclusive formula based upon good current science, and you will probably save money by purchasing all these nutrients in one bio-chemically balanced product, rather than buying them separately."

"Biosyntrx is extremely pleased with the endorsement of our product by the largest and most active online AMD information and support community," said Spencer Thornton, MD, Biosyntrx President and CMO. "Based on recommendations from our customers and our recent "Certificate of Free Sale" awarded by the FDA and the Department of Health and Human Services, our formulations are being sold in more than 30 countries, as well as to the US government and the military. We are exceeding 300% sales growth in the last year, which we could not achieve without a high degree of physician and patient satisfaction."

About MD Support

Macular Degeneration Support is a 501(c) (3), worldwide public service organization founded in 1995 by Dan Roberts, who, as most of the organization's volunteers, is visually-impaired. Its work is guided by a 12-member professional advisory board comprised of leading doctors, rehabilitation specialists, and social workers.

The MD Support web site was recognized as the 2004 recipient of the "Distinguished Service Award" by the Low Vision Rehabilitation Section of the American Optometric Association, which describes the award as "the highest honor given by the LVRS to an organization or individual for contributions to low vision care and distinguished service to the general welfare of the public."

About Biosyntrx

Biosyntrx, founded in 2002, is a privately held, research-based ophthalmic company based in Lexington, South Carolina. It develops and markets nutraceutical products that support optimal eye and body health such as: Syntrx Complete (soon to be reformulated and renamed Oculair(TM)), containing optimal amounts of nutrients, including 7 mg of lutein and 3 mg of zeaxanthin, to help protect the eyes and body from the damaging effects of free radicals and the aging process; and "BioTears Oral GelCaps(TM), the most complete nutraceutical formulation addressing the complex inflammatory issues of age-related and surgically induced dry eye syndrome.

Biosyntrx is committed to proving the science that supports each formulation with cohort studies designed around ophthalmic clinical markers. For further information please visit or call Joe Kirkland, COO at 800-688-6815.

Biosyntrx, Inc.

CONTACT: Ellen Troyer MT MA, Executive Vice President, Chief ResearchOfficer of Biosyntrx, mobile, +1-415-860-9874, or Research Office,+1-719-227-7888, or

Read at

comments powered by Disqus